Immunotherapy represents a transformative strategy in oncology, aiming to empower the patient’s immune system to recognize and eradicate cancer cells. However, despite remarkable successes, a significant subset of patients exhibits resistance or suboptimal responses. The Karolinska team sought to decipher the cellular dynamics that contribute to these varied outcomes, centering their investigations on neutrophils within two distinct murine cancer models: melanoma and breast carcinoma. These granulocytes, although frontline defenders against pathogens, exhibit complex, often paradoxical, behavior in malignancies.

By employing genetically engineered mice completely lacking neutrophils, researchers created a fundamental contrast with normal counterparts possessing intact neutrophil populations. Remarkably, the absence of neutrophils was associated with amplified effectiveness of multiple immunotherapeutic modalities. Tumor volumes decreased more significantly, paralleled by an influx and heightened activation of cytotoxic T lymphocytes (CTLs) within the tumor niche. This phenomenon underscores a previously underappreciated suppressive influence neutrophils exert over the adaptive immune response prompted by therapy.

Delving deeper, the study elucidates a sophisticated feedback mechanism involving neutrophils and tumor signaling pathways. Following the initiation of immunotherapy, neutrophils themselves undergo a phenotypic modulation wherein they begin expressing programmed death-ligand 1 (PD-L1). PD-L1 is a critical immune checkpoint molecule that suppresses T cell-mediated tumor clearance by binding to PD-1 receptors on T cells, thereby attenuating their cytotoxic functions. This induction of PD-L1 expression on neutrophils is driven by interferon-gamma (IFN-γ), a type II interferon secreted by activated immune cells within the tumor milieu.

Crucially, when the research team selectively ablated PD-L1 or disrupted the IFN-γ receptor specifically on neutrophils, immunotherapeutic efficacy was restored to greater degrees. This compelling evidence demonstrates that the tumor microenvironment dynamically instructs neutrophils to adopt immune checkpoint properties that blunt T cell activity. Such findings challenge the prevailing conception of neutrophils as mere innate immune effectors and highlight their role as modulators of adaptive immune resistance in cancer.

The implications of this discovery are far-reaching. It establishes that the neutrophil response to cancer immunotherapy is not a static trait but is governed by extrinsic signals within the tumor’s immunological landscape. Consequently, therapeutic strategies that target neutrophil-mediated inhibition hold promise to synergize with existing immunotherapies, potentially overcoming resistance and refining treatment responses. This conceptual pivot points toward the development of combination therapies integrating immune checkpoint blockade with interventions designed to neutralize neutrophil-driven suppression.

Moreover, the translational relevance of the study is underscored by observations from human tumor samples. Analysis of specimens from lung cancer patients undergoing immunotherapy revealed similar neutrophil PD-L1 expression patterns, hinting that the interplay observed in murine models reflects conserved phenomena in human malignancies. This cross-species validation bolsters the clinical significance of targeting neutrophil-mediated pathways to augment immunotherapy outcomes.

These insights also invite a broader reconsideration of the tumor microenvironment’s composition and the intricate crosstalk among immune cell subsets. Neutrophils, once relegated to simple categorizations of pro-inflammatory or anti-inflammatory cells, are now appreciated as plastic entities capable of both promoting and suppressing tumor progression, contingent upon microenvironmental cues. The dynamic induction of inhibitory molecules such as PD-L1 represents a striking example of how tumors can hijack immune cells to construct barriers against eradication.

The study was the result of an international collaboration, bringing together expertise from institutions across Sweden, the United States, Germany, and China. Supported by funding from major agencies including the National Institutes of Health, the Swedish Cancer Society, and the Swedish Foundation for Strategic Research, the comprehensive nature of the research reflects a global commitment to advancing cancer immunology. Importantly, the investigators have declared no conflicts of interest, adding credibility to their groundbreaking conclusions.

In practical terms, these findings suggest that future cancer treatment regimens may need to incorporate strategies that either deplete neutrophils or inhibit their PD-L1 induction to unleash maximal T cell function. Such approaches could involve novel pharmacological inhibitors, antibody-based therapies against neutrophil-expressed PD-L1, or modulation of IFN-γ signaling pathways. The goal is to dismantle the immunosuppressive barricades within tumors that limit the curative potential of current immunotherapies.

Ultimately, this research deepens our understanding of the immune landscape in cancer and highlights the nuanced roles played by different leukocyte populations. It emphasizes the importance of a systems biology approach to cancer therapy, where combinatorial treatments targeting multiple cellular and molecular mechanisms stand a better chance of success. As immunotherapy continues to revolutionize cancer care, dissecting the multifaceted interactions within the tumor milieu remains paramount for overcoming resistance and achieving durable remissions.

The Karolinska Institutet study encapsulates a pivotal moment in cancer immunology—recognizing neutrophils not just as effectors but also as modulators of immune evasion. Such nuanced insights will undoubtedly steer the field towards more sophisticated, rationally designed therapies, paving the way for improved patient outcomes in the battle against cancer.

Subject of Research: Neutrophil regulation in cancer immunotherapy through type II interferon signaling.

Article Title: Neutrophil regulation of immunotherapy for cancer is controlled by type II interferon

News Publication Date: 15 June 2026

Web References: https://doi.org/10.1016/j.immuni.2026.05.014

References: Shengduo Pei, Yueyun Pan, Heng Liang, Li Lei, Qirong Lin, Jiarui Mi, Jeffrey V Ravetch, Oliver Soehnlein, Mikael C.I. Karlsson, Immunity, 15 June 2026.

Keywords: Cancer, Immunotherapy, Neutrophils, PD-L1, Interferon-gamma, Tumor microenvironment, T cells, Immune checkpoints, Immunosuppression, Leukocytes, Granulocytes, Tumor resistance

A recent study published in the Journal of Translational Medicine by Chen et al. presents compelling evidence that Dynamin 1, a GTPase enzyme known for its role in endocytosis, plays a crucial role in promoting colorectal cancer progression. This research highlights the complex interplay between cellular mechanisms and cancer biology, emphasizing the significance of Dynamin 1 in enhancing the malignant characteristics of colorectal tumors through the activation of the PI3K/Akt signaling pathway.

Dynamin 1 is traditionally recognized for its function in clathrin-mediated endocytosis, allowing cells to internalize various molecules, including receptors and nutrients. However, this study uncovers a novel aspect of Dynamin 1, illustrating its involvement not merely in cellular uptake but also in the signaling processes that drive cancer progression. The researchers employed a series of in vitro and in vivo experiments that demonstrated how increased expression levels of Dynamin 1 corresponded with enhanced cell proliferation and invasive potential in colorectal cancer cell lines.

The study meticulously outlines the experimental approaches employed to investigate the role of Dynamin 1 in colorectal cancer. These included gene expression analyses, functional assays to evaluate cell migration and invasion, and the use of specific inhibitors to dissect the signaling pathways involved. By manipulating Dynamin 1 levels through genetic knockdown and overexpression techniques, the researchers were able to observe significant changes in cell behavior, underscoring the importance of this protein in tumor biology.

Further examination revealed that the activation of the PI3K/Akt pathway was a pivotal aspect of Dynamin 1’s function in colorectal cancer. The PI3K/Akt signaling cascade is known for its involvement in various cellular processes, including growth factor signaling, metabolism, and apoptosis regulation. The study found that when Dynamin 1 was overexpressed, there was a corresponding increase in Akt phosphorylation, indicative of pathway activation. This correlation suggests that Dynamin 1 might serve as an upstream regulator of the PI3K/Akt signaling cascade.

The implications of these findings cannot be understated. As the activation of the PI3K/Akt pathway is often associated with poor prognosis in cancer patients, understanding how Dynamin 1 contributes to this pathway could open new avenues for targeted therapies. The potential for developing inhibitors that specifically target Dynamin 1 or its interaction with the PI3K/Akt signaling pathway presents an exciting prospect for clinicians and researchers working in the field of cancer therapy.

Moreover, the study discusses the potential mechanisms through which Dynamin 1 activates the PI3K/Akt pathway. The authors hypothesize that the endocytic role of Dynamin 1 may facilitate the internalization of growth factor receptors, ultimately leading to enhanced receptor signaling and increased pathway activation. This relationship highlights a critical intersection between cellular trafficking systems and oncogenic signaling pathways, proposing that modifications in endocytosis could have far-reaching effects on tumor behavior.

The researchers also investigated the expression levels of Dynamin 1 in clinical colorectal cancer specimens, drawing a parallel between laboratory findings and patient outcomes. Such translational research is vital for validating preclinical insights and determining their relevance in clinical settings. The correlation between elevated Dynamin 1 expression and advanced clinical stages of colorectal cancer reinforces the idea that this protein could serve as a prognostic biomarker, aiding in patient stratification and treatment planning.

While the study emphasizes the vital role of Dynamin 1 in colorectal cancer progression, it also raises questions about broader implications. Given the widespread involvement of the PI3K/Akt signaling pathway in various cancer types, could interventions targeting Dynamin 1 have applications beyond colorectal cancer? This question invites further research into the potential universality of Dynamin 1’s role in cancer biology, as well as its function in other signaling pathways associated with malignancies.

In the context of personalized medicine, understanding individual variations in Dynamin 1 expression and activity could inform treatment decisions. The study by Chen et al. lays crucial groundwork for future investigations aimed at deciphering the molecular complexities of colorectal cancer and identifying specific cohorts that might benefit from targeted therapies focused on Dynamin 1 modulation.

The comprehensive nature of this research signifies a promising advance in our understanding of cancer biology and suggests essential areas for further exploration. As the scientific community continues to interrogate the mechanisms driving cancer progression, studies such as this one will be invaluable in shaping therapeutic strategies that are not only effective but also tailored to the molecular makeup of individual tumors.

In summary, the work of Chen and colleagues sheds light on the multifaceted role of Dynamin 1 in colorectal cancer progression through the activation of the PI3K/Akt signaling pathway. By elucidating this relationship, the authors contribute to a growing body of literature that aims to dissect the intricate networks of signaling pathways driving cancer. As researchers work toward developing novel therapeutic approaches targeting these pathways, the insights provided by this study will undoubtedly be instrumental in advancing our understanding of cancer and improving patient outcomes.

Subject of Research: The role of Dynamin 1 in colorectal cancer progression through the PI3K/Akt signaling pathway.

Article Title: Dynamin 1 promotes colorectal cancer progression by activating the PI3K/Akt signaling pathway.

Article References:

Chen, R., Hong, R., Chen, L. et al. Dynamin 1 promotes colorectal cancer progression by activating the PI3K/Akt signaling pathway.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07600-1

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07600-1

Keywords: Dynamin 1, colorectal cancer, PI3K/Akt signaling pathway, cancer progression, targeted therapy.